Pipeline

Pipeline

Most of the time, the immune system is your best friend. Complex processes and interactions regulate the body’s defense towards viruses, bacteria and tumor development. However, the immune system can also mistakenly attack healthy cells and tissues. Diseases like rheumatoid arthritis and multiple sclerosis, as well as potentially fatal overreactions to viral infections, are examples of such disorders of the immune system.

Over the last decade, the treatment of immunological diseases has improved dramatically. However, current drugs have several shortcomings, such as adverse side effects, administration forms that often require visits to the hospital, and poor response or resistance in some patients.

Against this background, there is a need for efficacious, tolerable and convenient drugs that are able to modify or prevent disease progression at an early stage. Bringing such therapies forward is the scope for Cyxone’s aspirations in its three development programs within the areas of rheumatoid arthritis, virally induced respiratory disorders (such as Covid-19) and multiple sclerosis.

Project Status

Preclinical
Phase 1
Phase 2
Phase 3
Rheumatoid Arthritis
Covid-19
Multiple Sclerosis

Our Drug Projects

Rheumatoid Arthritis (Rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Read More

Covid-19 (Rabeximod)

Inhibits the release of multiple cytokines without suppressing the general immune system

Read More

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Read More